Statistics from Altmetric.com
Several meta-analyses, including a Cochrane analysis, performed previously on the same topic, came to the conclusion that ‘hydrolyzed formula is recommended in the first 4–6 months of life for the primary prevention of allergic diseases’.1–3 In 2012, the Food and Drug Administration (FDA) concluded that a particular partial whey hydrolysate could reduce the risk of eczema in high-risk infants. Boyle and colleagues, however, come to a different conclusion, and state that the current guidelines recommending hydrolysates to prevent allergic disease in high-risk infants are not supported.
This meta-analysis included data from 37 intervention trials including over 19 000 participants. The review was performed in accordance with PRISMA guidance. Heterogeneity and publication …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.